From a clinical point of view, anosmia and ageusia have a low prevalence in infected children and increase with the age of the COVID-19 patient50,56, which seems to be consistent with the protein expression of ACE2 that we have observed in the mice olfactory system. This evidence concerns the gene ACE2 and Ageusia.